June 6-9, 2012, in Berlin, Germany | |||||
Company (Location) |
Product |
Description |
Indication |
Status |
Date |
Abbott (Abbott Park, Ill.) |
Humira |
Adalimumab |
Rheumatoid arthritis |
Data from two long-term, open-label studies showed that Humira treatment for up to 10 years continued to maintain improvement in disease activity |
6/7/12 |
BioCryst Pharmaceuticals Inc. (Research Triangle Park, N.C.) |
BCX4208 |
Enzyme inhibitor |
Gout |
Phase IIb data showed it undergoes renal elimination, is not metabolized by liver cells and does not induce or inhibit CYP isoforms or common drug transporters |
6/7/12 |
Bristol-Myers Squibb Co. (New York) |
Orencia |
Abatacept |
Rheumatoid arthritis |
Met its primary endpoint, as measured by noninferiority, and demonstrated that when used with methotrexate it achieved comparable rates of efficacy to Humira |
6/7/12 |
Genentech Inc. (South San Francisco) |
Actemra |
Tocilizumab; single-agent treatment |
Rheumatoid arthritis |
Data showed that adult RA patients who received Actemra experienced a significantly greater improvement in disease activity after 24 weeks compared to patients who received Humira |
6/7/12 |
Janssen Research & Development LLC (unit of New Brunswick, N.J.-based Johnson & Johnson) |
Stelara |
Ustekinumab |
Active psoriatic arthritis |
Phase III data showed that it experienced significant improvements in signs and symptoms of the disease |
6/7/12 |
Savient Pharmaceuticals Inc. (East Brunswick, N.J.) |
Krystexxa |
Pegloticase; pegylated uric acid specific enzyme |
Chronic kidney disease |
Data showed there was no difference in rates of response to Krystexxa by CKD stage and that it did not affect estimated glomerular filtration rate levels in patients with or without CKD |
6/7/12 |
Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. |